Display options
Cite
Looyenga BD, Cherni I, Mackeigan JP, et al. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011;4(2):59-70doi: 10.1593/tlo.10241.
Looyenga, B. D., Cherni, I., Mackeigan, J. P., & Weiss, G. J. (2011). Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Translational oncology, 4(2), 59-70. https://doi.org/10.1593/tlo.10241
Looyenga, Brendan D, et al. "Tailoring tyrosine kinase inhibitors to fit the lung cancer genome." Translational oncology vol. 4,2 (2011): 59-70. doi: https://doi.org/10.1593/tlo.10241
Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011 Apr 01;4(2):59-70. doi: 10.1593/tlo.10241. PMID: 21461169; PMCID: PMC3069649.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2011 Apr 01;4(2):59-70. doi: 10.1593/tlo.10241.

Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

Translational oncology

Brendan D Looyenga, Irene Cherni, Jeffrey P Mackeigan, Glen J Weiss

Affiliations

  1. Van Andel Research Institute, Systems Biology, Grand Rapids, MI, USA.

PMID: 21461169 PMCID: PMC3069649 DOI: 10.1593/tlo.10241

Abstract

Tyrosine kinase inhibitors (TKIs) have been in use as cancer therapeutics for nearly a decade, and their utility in targeting specific malignancies with defined genetic lesions has proven to be remarkably effective. Recent efforts to characterize the spectrum of genetic lesions found in non-small cell lung carcinoma (NSCLC) have provided important insights into the molecular basis of this disease and have also revealed a wide array of tyrosine kinases that might be effectively targeted for rationally designed therapies. The findings of these studies, however, also provide a cautionary tale about the limitations of single-agent therapies, which fail to account for the genetic heterogeneity and pathway redundancy that characterize advanced NSCLC. Emergence of drug resistance mechanisms to specific TKIs, such as gefitinib and erlotinib, suggests that more sophisticated chemotherapeutic paradigms that target multiple pathways at the same time will be required to effectively treat this disease.

References

  1. Cancer Cell. 2002 Mar;1(2):117-23 - PubMed
  2. J Clin Oncol. 2008 May 20;26(15):2450-6 - PubMed
  3. Clin Cancer Res. 2006 Dec 15;12(24):7222-31 - PubMed
  4. Br J Cancer. 2009 Jul 21;101(2):327-34 - PubMed
  5. Cancer Res. 2008 Mar 15;68(6):1935-44 - PubMed
  6. Cancer Res. 1989 Dec 1;49(23):6474-9 - PubMed
  7. Nat Rev Drug Discov. 2006 Oct;5(10):835-44 - PubMed
  8. Nature. 2008 Oct 16;455(7215):930-5 - PubMed
  9. Science. 2001 Aug 3;293(5531):876-80 - PubMed
  10. Clin Cancer Res. 2008 Nov 15;14(22):7519-25 - PubMed
  11. Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40 - PubMed
  12. Cancer Res. 2008 May 1;68(9):3389-95 - PubMed
  13. Science. 2002 Jul 5;297(5578):63-4 - PubMed
  14. Oncogene. 2009 Aug;28 Suppl 1:S14-23 - PubMed
  15. Curr Opin Genet Dev. 2005 Feb;15(1):62-8 - PubMed
  16. Nature. 2010 May 27;465(7297):473-7 - PubMed
  17. J Thorac Oncol. 2009 Aug;4(8):994-1001 - PubMed
  18. Lancet Oncol. 2010 Jul;11(7):619-26 - PubMed
  19. Cancer Res. 2007 Dec 1;67(23):11300-8 - PubMed
  20. Cell. 2010 Apr 2;141(1):69-80 - PubMed
  21. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32 - PubMed
  22. Lung Cancer. 2010 Sep;69(3):272-8 - PubMed
  23. Lung Cancer. 2007 Mar;55(3):349-55 - PubMed
  24. Clin Cancer Res. 2009 Aug 15;15(16):5267-73 - PubMed
  25. Clin Exp Metastasis. 2008;25(6):685-93 - PubMed
  26. Nat Rev Cancer. 2005 Apr;5(4):275-84 - PubMed
  27. Adv Cancer Res. 2009;102:1-17 - PubMed
  28. Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):841-7 - PubMed
  29. Chem Biol. 2005 Jun;12(6):621-37 - PubMed
  30. Clin Exp Metastasis. 2008;25(8):843-54 - PubMed
  31. Drug Metab Dispos. 2008 Jul;36(7):1267-74 - PubMed
  32. Cell. 2010 Jun 25;141(7):1117-34 - PubMed
  33. Semin Oncol. 2006 Aug;33(4):407-20 - PubMed
  34. Nat Rev Drug Discov. 2010 Jan;9(1):17-8 - PubMed
  35. Cancer Lett. 2009 Jul 18;280(1):1-14 - PubMed
  36. J Clin Oncol. 2010 Jan 10;28(2):357-60 - PubMed
  37. Nat Rev Cancer. 2005 Mar;5(3):172-83 - PubMed
  38. Nat Rev Cancer. 2010 Feb;10(2):130-7 - PubMed
  39. Clin Cancer Res. 2009 Apr 1;15(7):2207-14 - PubMed
  40. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  41. Clin Cancer Res. 2008 Jul 1;14(13):4275-83 - PubMed
  42. J Thorac Oncol. 2009 Dec;4(12):1450-4 - PubMed
  43. J Clin Oncol. 2008 Nov 20;26(33):5407-15 - PubMed
  44. Clin Cancer Res. 2010 Jul 1;16(13):3507-16 - PubMed
  45. Nature. 2010 Apr 15;464(7291):999-1005 - PubMed
  46. J BUON. 2008 Apr-Jun;13(2):263-5 - PubMed
  47. Hematology Am Soc Hematol Educ Program. 2009;:636-42 - PubMed
  48. Cancer Res. 2006 Jun 1;66(11):5542-8 - PubMed
  49. Nature. 2001 May 17;411(6835):355-65 - PubMed
  50. Nat Rev Cancer. 2009 Nov;9(11):798-809 - PubMed
  51. Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 - PubMed
  52. Nat Clin Pract Oncol. 2008 Nov;5(11):623 - PubMed
  53. J Clin Oncol. 2009 Sep 10;27(26):4247-53 - PubMed
  54. Clin Cancer Res. 2006 Mar 1;12(5):1647-53 - PubMed
  55. Cancer Cell. 2008 Apr;13(4):311-20 - PubMed
  56. Nature. 2009 Dec 24;462(7276):1070-4 - PubMed
  57. Nat Rev Cancer. 2007 Sep;7(9):673-83 - PubMed
  58. Curr Cancer Drug Targets. 2010 Nov;10(7):683-94 - PubMed
  59. Anticancer Agents Med Chem. 2010 Mar;10(3):236-49 - PubMed
  60. Clin Cancer Res. 2010 Jan 1;16(1):291-303 - PubMed
  61. Nature. 2008 Oct 23;455(7216):1069-75 - PubMed
  62. Curr Opin Pharmacol. 2008 Aug;8(4):413-8 - PubMed
  63. IDrugs. 2010 May;13(5):332-45 - PubMed
  64. Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 - PubMed
  65. J Proteome Res. 2010 Aug 6;9(8):4102-12 - PubMed
  66. Oncologist. 2010;15(5):436-46 - PubMed
  67. J Clin Invest. 2008 Jul;118(7):2609-19 - PubMed
  68. Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 - PubMed
  69. J Clin Oncol. 2010 Jun 10;28(17):2925-35 - PubMed
  70. Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S20-6 - PubMed
  71. PLoS Med. 2005 Jan;2(1):e17 - PubMed
  72. Nature. 2010 Apr 15;464(7291):993-8 - PubMed
  73. J Clin Oncol. 2005 Nov 1;23(31):8081-92 - PubMed
  74. Leukemia. 2008 Sep;22(9):1790-2 - PubMed
  75. J Clin Oncol. 2005 Sep 1;23(25):5892-9 - PubMed
  76. Mol Pharmacol. 2009 Jan;75(1):196-207 - PubMed
  77. Cancer Res. 2010 May 15;70(10):3857-60 - PubMed
  78. Nat Rev Cancer. 2010 Mar;10(3):165-80 - PubMed
  79. Nat Rev Clin Oncol. 2009 Jul;6(7):395-404 - PubMed
  80. Nature. 2010 Feb 18;463(7283):899-905 - PubMed
  81. Nat Rev Clin Oncol. 2009 Oct;6(10):569-79 - PubMed
  82. Mol Cell Biol. 1989 Mar;9(3):1165-72 - PubMed
  83. Proc Natl Acad Sci U S A. 1979 Apr;76(4):1804-8 - PubMed
  84. Virus Res. 2008 Jun;134(1-2):157-70 - PubMed
  85. Nat Rev Cancer. 2008 Jan;8(1):11-23 - PubMed
  86. N Engl J Med. 2005 Feb 24;352(8):786-92 - PubMed
  87. Nat Rev Cancer. 2008 Oct;8(10):755-68 - PubMed
  88. Curr Cancer Drug Targets. 2010 Aug;10(5):462-83 - PubMed
  89. Proc Natl Acad Sci U S A. 1978 Sep;75(9):4102-6 - PubMed
  90. Curr Opin Investig Drugs. 2004 Jun;5(6):597-604 - PubMed
  91. J Clin Oncol. 2010 Apr 10;28(11):1835-42 - PubMed
  92. Nat Rev Drug Discov. 2006 Apr;5(4):279-80 - PubMed
  93. Cell. 2010 May 14;141(4):583-94 - PubMed
  94. J Clin Oncol. 2010 Mar 10;28(8):1387-94 - PubMed
  95. Genes Dev. 2007 Dec 15;21(24):3214-31 - PubMed
  96. Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102 - PubMed
  97. Rev Recent Clin Trials. 2007 May;2(2):117-20 - PubMed
  98. Am J Pathol. 2007 Jan;170(1):366-76 - PubMed
  99. Nat Rev Clin Oncol. 2010 Sep;7(9):493-507 - PubMed
  100. Clin Cancer Res. 2008 May 15;14(10):2895-9 - PubMed
  101. Lung Cancer. 2008 Jun;60 Suppl 2:S3-9 - PubMed
  102. Oncogene. 2010 Aug 26;29(34):4741-51 - PubMed
  103. Clin Lung Cancer. 2009 Nov;10(6):395-404 - PubMed
  104. Thorac Surg Clin. 2006 Nov;16(4):379-96, vi - PubMed
  105. Cell. 2009 Nov 25;139(5):871-90 - PubMed
  106. Antiviral Res. 2010 Jan;85(1):210-31 - PubMed
  107. Breast Cancer Res. 2009;11(5):R68 - PubMed
  108. Cancer Res. 2010 Feb 1;70(3):868-74 - PubMed
  109. J Biol Chem. 2002 Nov 29;277(48):46265-72 - PubMed
  110. Br J Cancer. 2008 Jul 8;99(1):1-5 - PubMed
  111. Clin Cancer Res. 2010 Jun 1;16(11):3078-87 - PubMed
  112. Nature. 2007 Aug 2;448(7153):561-6 - PubMed
  113. Oncogene. 2009 Aug;28 Suppl 1:S38-45 - PubMed
  114. Br J Cancer. 2006 Oct 23;95(8):1013-9 - PubMed
  115. Cancer Cell. 2010 Jan 19;17(1):77-88 - PubMed
  116. Mol Cancer Ther. 2010 Jun;9(6):1525-35 - PubMed
  117. J Clin Oncol. 2010 Jan 10;28(2):193-201 - PubMed
  118. Lung Cancer. 2011 May;72(2):199-204 - PubMed
  119. J Thorac Oncol. 2010 Sep;5(9):1382-90 - PubMed
  120. Nat Rev Clin Oncol. 2010 Jul;7(7):401-14 - PubMed
  121. Expert Opin Ther Pat. 2009 Jun;19(6):731-51 - PubMed
  122. Oncology (Williston Park). 2009 Nov 30;23(13):1133-40 - PubMed
  123. Nature. 2007 Dec 6;450(7171):893-8 - PubMed
  124. Cancer Res. 2010 Feb 15;70(4):1625-34 - PubMed
  125. Expert Opin Ther Targets. 2010 Jan;14(1):77-94 - PubMed
  126. Oncologist. 2003;8(6):531-8 - PubMed
  127. N Engl J Med. 2008 Sep 25;359(13):1367-80 - PubMed
  128. Science. 1992 Dec 11;258(5089):1798-801 - PubMed
  129. Science. 2007 May 18;316(5827):1039-43 - PubMed
  130. Cancer Sci. 2010 Jan;101(1):167-72 - PubMed
  131. PLoS Med. 2005 Mar;2(3):e73 - PubMed
  132. Cancer Res. 2010 Feb 1;70(3):1063-71 - PubMed
  133. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 - PubMed
  134. Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 - PubMed
  135. Leukemia. 2007 Aug;21(8):1658-68 - PubMed
  136. J Clin Oncol. 2008 Jun 10;26(17):2846-53 - PubMed
  137. Eur J Cancer. 2010 Jul;46(10):1773-80 - PubMed
  138. Expert Opin Investig Drugs. 2010 Aug;19(8):931-45 - PubMed
  139. J Clin Oncol. 2010 May 1;28(13):2174-80 - PubMed
  140. Clin Cancer Res. 2009 May 15;15(10):3484-94 - PubMed
  141. Int J Cancer. 1999 Oct 29;83(3):415-23 - PubMed
  142. Blood. 2005 Mar 1;105(5):1862-6 - PubMed
  143. Curr Opin Cell Biol. 2006 Oct;18(5):516-23 - PubMed
  144. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70 - PubMed
  145. Clin Lung Cancer. 2004 Dec;6 Suppl 1:S24-9 - PubMed
  146. Recent Results Cancer Res. 2010;184:45-59 - PubMed
  147. J Clin Oncol. 2004 Mar 1;22(5):759-61 - PubMed
  148. Cold Spring Harb Symp Quant Biol. 2005;70:483-8 - PubMed
  149. J Clin Oncol. 2009 May 20;27(15):2523-9 - PubMed
  150. Ann N Y Acad Sci. 2004 Dec;1028:351-60 - PubMed
  151. Nat Rev Clin Oncol. 2009 Oct;6(10):587-95 - PubMed
  152. N Engl J Med. 2009 Sep 3;361(10):1018-20 - PubMed
  153. Cancer Res. 2009 Aug 15;69(16):6515-21 - PubMed
  154. Curr Opin Hematol. 2010 Mar;17(2):91-6 - PubMed
  155. Cancer Cell. 2004 Dec;6(6):535-8 - PubMed

Publication Types